Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $175 | $192 | $157 | $184 |
| Short-Term Investments | $177 | $116 | $111 | $60 |
| Receivables | $52 | $32 | $40 | $42 |
| Inventory | $41 | $48 | $22 | $26 |
| Other Curr. Assets | $30 | $32 | $25 | $20 |
| Total Curr. Assets | $476 | $420 | $356 | $332 |
| Property Plant & Equip (Net) | $12 | $11 | $11 | $11 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $16 | $16 | $16 | $16 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $201 | $206 | $208 | $211 |
| Other NC Assets | $8 | $8 | $8 | $10 |
| Total NC Assets | $237 | $241 | $243 | $249 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $712 | $661 | $599 | $581 |
| Liabilities | – | – | – | – |
| Payables | $6 | $9 | $2 | $2 |
| Short-Term Debt | $3 | $3 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $32 | $0 | $0 |
| Other Curr. Liab. | $115 | $75 | $93 | $97 |
| Total Curr. Liab. | $124 | $118 | $97 | $101 |
| LT Debt | $7 | $7 | $8 | $8 |
| Deferred Rev, NC | $32 | $32 | $32 | $32 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $15 | $9 | $5 | $2 |
| Total NC Liab. | $53 | $48 | $45 | $41 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $10 | $10 | $10 | $10 |
| Total Liabilities | $177 | $166 | $142 | $142 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$476 | -$495 | -$513 | -$521 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $1,012 | $990 | $970 | $960 |
| Total Equity | $535 | $495 | $457 | $438 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $712 | $661 | $599 | $581 |
| Net Debt | -$165 | -$182 | -$147 | -$174 |